WaferGen and IBBL Sign Agreement for MDx Collaboration

WaferGen Biosystems, Inc. (Fremont, CA, USA) and the Integrated BioBank of Luxembourg (IBBL) announced an agreement to establish a relationship that will expand the use of the WaferGen SmartChip Real-Time polymerase chain reaction (RT-PCR) system throughout Europe and advance personalized medicine.

IBBL will purchase a SmartChip RT-PCR system to provide genomic analysis services for the company's own scientific programs and for other groups in Europe. IBBL will use the SmartChip system for discovery and validation of gene expression patterns (biomarkers) on a single platform.

WaferGen will establish its European Headquarters at the IBBL facilities in Luxembourg very shortly. The Luxembourg Government has recently launched a biomedical initiative to harness genomics technologies for the study of human health problems and increase Luxembourg's personalized medicine capabilities.

Alnoor Shivji, chairman and CEO, WaferGen, said, "This strategic relationship with IBBL, a world class biobank that collects, analyzes and stores samples, enables WaferGen to access best-annotated patient samples for future diagnostic products. It also establishes a beachhead in Europe to unlock the short- and long-term revenue potential of the WaferGen SmartChip system

Related Links:
WaferGen Biosystems, Inc.
Integrated BioBank of Luxembourg